Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma

• References

• 1 Tsur N, Kogan Y, Avizov-Khodak E. et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med 2019; 17 (01) 338
• 2 Burns MC, O'Donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016; 4 (08) 867-873
• 3 Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med 2016; 4 (14) 269
• 4 Robert C, Ribas A, Hamid O. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018; 36 (17) 1668-1674
• 5 Cancer Research Institute. Immunotherapy for Melanoma. Accessed August 20, 2020 at: https://www.cancerresearch.org/immunotherapy/cancer-types/melanoma